Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.

  • 1 of 1

The National Institute for Health and Care Excellence (NICE) is recommending in draft guidance that pembrolizumab (Keyruda) be made available on the NHS for the treatment of some patients with advanced melanoma (pictured)

NICE recommends in draft guidance that pembrolizumab be made available to patients with melanoma where their disease has progressed despite being treated with other therapies

Source  Shutterstock.com